Ateb licenses Walgreens’ entire portfolio of prescription alignment patents
RALEIGH, N.C. — Ateb on Thursday announced it has reached an agreement to license Walgreens' entire portfolio of prescription alignment patents in an effort to continue to improve overall health care, demonstrate the value of medication synchronization and increase patient adherence rates.
By securing this licensing, Ateb has insured that its customers may continue to use Ateb's Time My Meds solution. Time My Meds helps patients improve their overall health and gives pharmacists the opportunity to administer additional services, such as immunizations, comprehensive medication reviews and wellness programs. Ateb’s Adherence Solutions for pharmacy help increase medication adherence, generate prescription sales and improve patient loyalty, the company noted.
"The time to focus on the way pharmacy impacts how health care is delivered is now, and Ateb believes pharmacy is the best solution for affordable, effective health care," the company stated. "As trusted, accessible healthcare experts, pharmacists are perfectly positioned to advise patients on their medication therapy and guide patients to better healthcare outcomes."
Ateb reported more than 250,000 patients are already being managed in Time My Meds, and pharmacies using Time My Meds continue to deliver increased patient medication adherence rates and improved patient health.
FDA issues warning letter to Zarbee’s for making treatment claims regarding its supplement products
SILVER SPRING, Md. — The Food and Drug Administration in late June issued a warning letter to Zarbee's for making therapeutic claims regarding a dietary supplement product. "The therapeutic claims on your website establish that the products are drugs because they are intended for use in the cure, mitigation, treatment or prevention of disease," the agency wrote. "[I]ntroducing or delivering these products for introduction into interstate commerce for such uses violates the Act."
Examples of some of the treatment claims made by Zarbees include that its Zarbee’s Naturals Children’s Cough Syrup-Grape “calms coughs.”
The agency also found fault with Zarbee's customer testimonials on its site, and criticized the company for "liking" testimonials on its Facebook page. "Zarbees 'liked' the following comment made on Feb. 11, 2014," the agency wrote, regarding the company's children’s Sleep remedy. "[Customer:] 'I received the free sample … and … gave it to my daughter … I could not believe how well it worked! She was recently diagnosed with ADHD and put on medication … causing insomnia.'"
Zarbee's has until mid-July to respond to the FDA warning letter. "Failure to promptly correct these violations may result in legal action without further notice, including seizure and/or injunction," the agency warned.
Fred’s Super Dollar posts $191.2 million in June sales, up 2%
MEMPHIS, Tenn. — Fred's Super Dollar on Thursday reported sales of $191.2 million, an increase of 2%, for the five-week month of June, which ended July 5.
Comparable-store sales for the month decreased 0.6% compared with a 4.5% increase in the same period last year.
"Comparable-store sales declined slightly for June, with the fourth week of the month being unusually soft as we were unable to place our new ad program for that week," stated Bruce Efird, Fred's CEO. "For the weeks that the new ad program were in effect, sales and customer traffic patterns improved noticeably. Our pharmacy department continued to experience strong growth in June, highlighted by ongoing increases in both comparable scripts and sales. Additionally, sales for EIRIS Health Services, our specialty pharmacy division, accelerated and exceeded plan," he said.
"Looking forward, July will be the first month that all the elements of our new marketing plan come together, including in-store marketing initiatives that promote the diverse product mix offered by our stores, together with our new, fully implanted ad program," Efird continued. "We also will begin an aggressive clearance program in July to clear unproductive SKUs and exit or reduce product categories that do not align with our convenience center model."
Fred's total sales for the first five months of fiscal 2014 were $840.9 million, approximately flat compared with $841.1 million for the same period last year. On a comparable-store basis, year-to-date sales decreased 1.3% versus flat sales for the year-earlier period.
Loading Post Please Wait...